​

Acumen Pharmaceuticals Stock (NASDAQ:ABOS)

ForecastRevenueOwnershipFinancialsChartTranscripts
Acumen Pharmaceuticals by TradingView

Previous Close

$1.60

52W Range

$1.53 - $5.09

50D Avg

$1.98

200D Avg

$2.63

Market Cap

$94.33M

Avg Vol (3M)

$312.44K

Beta

0.04

Div Yield

-

ABOS Company Profile

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

51

IPO Date

Jul 01, 2021

Website

ABOS Performance

ABOS Financial Summary

Dec 23Dec 22Dec 21
Revenue---
Operating Income$-61.14M$-45.24M$61.57M
Net Income$-52.37M$-40.48M$-181.68M
EBITDA$-60.95M$-45.07M$61.58M
Basic EPS$-1.08$-1.00$-9.06
Diluted EPS$-1.08$-1.00$-9.06

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q3 24Nov 12, 24 | 1:17 PM
Q2 24Aug 13, 24 | 11:17 AM
Q1 24May 14, 24 | 12:46 PM

Peer Comparison

TickerCompany
TERNTerns Pharmaceuticals, Inc.
AMLXAmylyx Pharmaceuticals, Inc.
MREOMereo BioPharma Group plc
DAWNDay One Biopharmaceuticals, Inc.
XFORX4 Pharmaceuticals, Inc.
HOOKHOOKIPA Pharma Inc.
INZYInozyme Pharma, Inc.